Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
MARKET INSIGHTS
The global SUS (Single Use System) for Biopharma Process market was valued at USD 4.98 billion in 2023 and is projected to reach USD 18.92 billion by 2030, at a CAGR of 21.0% during the forecast period. This growth is primarily driven by the increasing adoption of single-use technologies in biopharmaceutical manufacturing due to their cost-effectiveness and flexibility compared to traditional stainless steel systems.
SUS (Single Use System) for Biopharma Process refers to biopharmaceutical manufacturing (bioprocessing) equipment designed to be used once (or for a single manufacturing campaign) and then discarded. These systems are increasingly preferred for their ability to reduce cross-contamination risks and minimize validation requirements, particularly in multi-product facilities.
The market is segmented into single-use bioreactors, disposable sterile bags, and disposable filtration systems. Among these, disposable sterile bags hold the largest market share (approximately 45%) due to their extensive use across various bioprocessing steps from upstream to downstream processing. Disposable filtration systems follow closely, driven by stringent regulatory requirements for aseptic processing.
Geographically, North America dominates the market with 41% market share, followed by Europe at 32%, due to the concentration of biopharmaceutical companies and advanced healthcare infrastructure. The Asia-Pacific region shows the fastest growth rate (24.1% CAGR) attributed to increasing biopharmaceutical outsourcing and capacity expansion in countries like China and India.
Key market drivers include the growing biopharmaceutical pipeline (over 7,000 molecules in development as of 2023), increasing adoption of continuous manufacturing, and rising demand for personalized medicines. However, supply chain vulnerabilities and raw material price fluctuations remain significant challenges, particularly following pandemic-related disruptions.
The market is moderately concentrated, with the top 5 players holding 73% market share. Danaher, Thermo Fisher, and Sartorius dominate the premium segment, while regional players like Lepure China and JYSS Bio-Engineering compete effectively in growth markets.
Regulatory harmonization continues to improve, with FDA's 2023 guidance on single-use systems providing clearer guidance for manufacturers. The recent ISO 23447:2023 standard for single-use components further supports market growth through standardized quality expectations.
Rising Biologics Pipeline Demands Flexible Manufacturing
The global biologics market continues to expand with over 8,000 biologic drugs in development, driving unprecedented demand for single-use systems that offer flexibility and rapid deployment. Pharmaceutical companies are increasingly adopting SUS platforms to reduce time-to-market for critical therapies.
Cost Efficiency in Bioprocessing Operations
Single-use technologies demonstrate 30-40% reduction in capital expenditure compared to traditional stainless steel systems, while simultaneously reducing water and energy consumption by up to 60%. This economic advantage is crucial in competitive biopharma markets.
The shift toward personalized medicine requires flexible manufacturing platforms that can handle smaller batch sizes without compromising efficiency
Regulatory agencies worldwide are increasingly accepting single-use technologies, with over 85% of new biologics manufacturing facilities incorporating SUS components in their initial design phase.
MARKET CHALLENGES
Extractables and Leachables Concerns Remain Significant
Despite advances in material science, concerns regarding potential leachables from single-use systems interacting with sensitive biologics continue to challenge widespread adoption. Regulatory agencies require extensive validation studies that can add 12-18 months to development timelines.
Other Challenges
Supply Chain Vulnerabilities
The COVID-19 pandemic exposed vulnerabilities in single-use component supply chains, with lead times for certain filters and connectors extending to 9 months during peak demand. This has prompted regulatory agencies to examine supply chain security as a critical factor.
Sterilization Validation Complexity
Each product contact surface requires complete sterilization validation, with gamma radiation emerging as the preferred method. However, inconsistent radiation absorption rates across complex geometries present ongoing validation challenges.
High Initial Implementation Costs
While single-use systems offer long-term savings, the initial investment remains substantial. A complete SUS implementation for a mid-size biologics facility requires $8-12 million in capital equipment, with additional validation and training costs adding 25-30% to initial projections.
Emerging Markets Present Massive Growth Potential
The Asia-Pacific region shows 19.2% CAGR for single-use bioprocessing, with China and India accounting for 62% of new facility construction. This growth is driven by both local pharmaceutical expansion and multinational corporations establishing regional manufacturing hubs.
Continuous Manufacturing Integration
Regulatory agencies increasingly recognize the advantages of continuous manufacturing with single-use systems. The FDA's Emerging Technology Program has approved 14 continuous manufacturing platforms in the past three years, with 78% utilizing single-use components in critical path operations.
Advanced Therapy Medicinal Products (ATMPs) Expansion
The cell and gene therapy market requires ultra-flexible manufacturing capabilities that single-use systems provide. With over 1,200 cell and gene therapies in clinical development, the demand for single-use components in this sector is projected to grow at 24.7% CAGR through 2028.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Disposable Sterile Bags are the leading segment, encompassing a wide array of applications from media and buffer preparation to final product storage, which drives their essential role in virtually all bioprocessing workflows. The critical function of sterile bags in ensuring product integrity and preventing contamination, coupled with their relative simplicity and cost-effectiveness compared to complex hardware systems, makes them indispensable. This segments dominance is further reinforced by the flexibility it offers for scale-up and the increasing adoption of single-use technologies across both clinical and commercial manufacturing scales, requiring a continuous and high-volume supply of these consumables for various process steps. |
| By Application |
|
Bio-pharmacy represents the leading application segment, as it is the primary end-market for the biologics and advanced therapies manufactured using these systems. Pharmaceutical and biotechnology companies are the main drivers of SUS adoption, utilizing the technology for the production of monoclonal antibodies, vaccines, cell and gene therapies. The inherent advantages of single-use systems, such as reduced risk of cross-contamination and faster turnaround times between batches, align perfectly with the stringent quality requirements and the need for operational agility in bio-pharmaceutical development and production, solidifying this segment's dominant market position. |
| By End User |
|
Large Biopharmaceutical Companies are the dominant end-user segment due to their extensive and capital-intensive manufacturing operations for commercial-scale production. These industry leaders have the financial capacity to invest in the latest single-use technologies and are often early adopters, leveraging SUS to enhance manufacturing flexibility, accelerate time-to-market for new drugs, and optimize facility utilization. The scale of their operations necessitates a continuous and substantial demand for SUS components, making them the most influential customer group driving market standards, technological advancements, and volume purchases across the global supply chain. |
| By Process Stage |
|
Upstream Processing is the leading segment by process stage, as it is the foundation of biopharmaceutical manufacturing where cell culture and biomass production occur. The adoption of single-use bioreactors and associated mixing and storage systems in upstream operations is widespread because it significantly reduces cleaning validation requirements and minimizes the risk of microbial contamination during the critical cell growth phase. The flexibility offered by SUS in upstream processing allows for rapid process development, scale-up, and the production of multiple products within the same facility, which is a key strategic advantage for manufacturers operating in a dynamic and competitive landscape. |
| By System Scale |
|
Clinical Scale is the leading segment by system scale, representing a critical and high-growth phase in the drug development pipeline. The demand for SUS at the clinical scale is driven by the need for agile and cost-effective manufacturing of batches for clinical trials. Single-use systems are ideally suited for this stage as they allow for rapid process transfer from R&D, minimize capital investment compared to stainless-steel facilities, and provide the flexibility to manufacture multiple drug candidates concurrently. This segment's prominence is further amplified by the growing pipeline of biologics and personalized medicines, which often rely on SUS for their clinical-scale production due to the technology's ability to handle smaller, more specialized batches efficiently. |
A Consolidated Market Driven by Innovation and Strategic Expansion
The global Single-Use System (SUS) for biopharma process market is characterized by a high degree of consolidation, with the top five players collectively holding approximately 73% of the market share. These leading companies, including Danaher (through its subsidiary Cytiva), Thermo Fisher Scientific, Sartorius, and Merck, have established dominance through comprehensive product portfolios that cover the full spectrum of single-use technologies, from bioreactors to sterile bags and filtration systems. Their strong market position is reinforced by significant investment in research and development, global manufacturing and distribution networks, and strategic acquisitions to enhance their technological capabilities and geographic reach. These major players compete intensely on technology innovation, particularly in scaling up processes for commercial manufacturing and integrating advanced sensors for improved process control.
Beyond the market leaders, a significant number of specialized and emerging players compete by focusing on niche applications, specific technologies, or regional markets. Companies like ABEC are noteworthy for their expertise in designing and manufacturing large-scale custom single-use bioreactor systems. Regional specialists such as China's Lepure and Tofflon have gained substantial traction within the Asia-Pacific market, one of the fastest-growing regions. Other notable participants, including JYSS Bio-Engineering, Duoning Biotechnology, and AUSTAR, contribute to the competitive dynamics by offering competitive alternatives and fostering innovation in specific segments like disposable mixing systems and ancillary components, ensuring a diverse and dynamic competitive environment.
List of Key SUS (Single Use System) for Biopharma Process Companies ProfiledDanaher (Cytiva)
Merck KGaA
JYSS Bio-Engineering
Tofflon
Duoning Biotechnology
AUSTAR
SATAKE MultiMix
Corning Incorporated
Meissner Filtration Products, Inc.
Saint-Gobain
Parker Hannifin Corporation
The global Single Use System (SUS) for Biopharma Process market is undergoing significant expansion, demonstrating a remarkable compound annual growth rate (CAGR) of 21.0%. The market, valued at $4,979 million in 2023, is projected to reach a substantial $18,920 million by 2030. This growth is primarily driven by the inherent advantages of single-use technologies, which reduce cross-contamination risks and lower capital investment and validation costs compared to traditional stainless-steel systems. The market is characterized by its core components: single-use bioreactors, disposable sterile bags, and disposable filtration systems, which are central to modern biopharmaceutical manufacturing processes.
Other TrendsRegional Market Concentration
The market landscape shows a concentrated geographical distribution. North America and Europe are the two largest markets, each holding approximately a 32% share of the global market. This is closely followed by the Asia-Pacific region, which accounts for 31% of the market. This distribution reflects the established biopharmaceutical industries in North America and Europe, while highlighting the rapid growth potential within the Asia-Pacific region, where demand is steadily increasing.
Consolidated Competitive Landscape
The competitive environment is highly consolidated, with the top five players including Danaher, Thermo Fisher, Sartorius, Merck, and Lepure China collectively holding about 73% of the global market share. This concentration indicates a mature market where established companies with robust product portfolios and significant R&D capabilities dominate. Their focus is on continuous technological innovation to maintain a competitive edge.
Key Market Challenges and DriversKey challenges influencing market dynamics include raw material price fluctuations, which can impact production costs and competitiveness. The uncertainty of rapid technological change also presents a risk, as new or improved products could displace existing solutions. Increasing environmental awareness is placing greater emphasis on the sustainability, degradability, and recycling rates of single-use systems. Conversely, major growth opportunities lie in emerging markets, ongoing technological innovation that leads to better-performing and more cost-effective products, and the active establishment of industry standards to ensure product quality and safety.
Regional Analysis: SUS (Single Use System) for Biopharma Process MarketEurope
Europe represents a highly significant and mature market for Single-Use Systems, characterized by stringent regulatory oversight from the EMA and strong emphasis on quality and safety. The region has a well-established network of biopharmaceutical companies and CDMOs that are increasingly integrating SUS into both clinical and commercial-scale manufacturing. A key driver is the strong push towards reducing water and energy consumption, aligning with broader sustainability goals, which SUS effectively supports. Collaborative initiatives between academia, industry, and regulators help standardize practices and foster innovation. While adoption is widespread, market dynamics vary between Western European countries with advanced biotech hubs and emerging biopharma sectors in Eastern Europe, which are gradually increasing their uptake of single-use technologies.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for SUS, driven by a booming biopharmaceutical sector, increasing investments in healthcare infrastructure, and government initiatives to strengthen local drug manufacturing capabilities. Countries like China, Singapore, and South Korea are emerging as major hubs, with many new facilities being designed around single-use technology from the ground up. This offers a significant advantage over retrofitting traditional stainless-steel plants. Cost-effectiveness is a major factor, making SUS attractive for both domestic production and for the region's expanding role as a global CDMO center. However, market maturity varies greatly, with established players leading adoption while newer entrants navigate evolving regulatory landscapes and build supplier relationships.
South America
The South American market for Single-Use Systems is in a developing stage, with growth primarily fueled by Brazil's and, to a lesser extent, Argentina's biopharmaceutical industries. The primary adoption is currently within clinical-stage manufacturing and smaller-scale production, where the lower initial investment of SUS is a key advantage. Economic volatility and currency fluctuations can pose challenges for consistent investment in new technologies. Regulatory harmonization with international standards is an ongoing process, which influences the pace of adoption. The market potential is significant, driven by a growing focus on biologics and biosimilars, but it requires increased local manufacturing support and stable economic conditions to fully realize growth.
Middle East & Africa
This region presents an emerging opportunity for SUS adoption, though the market remains nascent. Growth is primarily concentrated in a few countries with strong government-backed initiatives to develop biopharmaceutical capabilities, such as those in the Gulf Cooperation Council (GCC) nations. The appeal of SUS lies in its ability to enable rapid setup of biomanufacturing facilities without the need for extensive utilities and validation associated with traditional systems. This is particularly attractive for building regional vaccine and biologic production capacity. Challenges include a currently limited local supplier base, requiring reliance on imports, and the need for further development of specialized technical expertise to support complex SUS implementations.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Biopharmaceutical companies
CDMOs
Equipment and consumable manufacturers
Investors and consultants
Regulatory and policy makers
-> Global SUS (Single Use System) for Biopharma Process market was valued at USD 4979 million in 2023.
What is the projected market size in 2030?
-> It is projected to reach USD 18920 million by 2030.
-> The market is growing at a CAGR of 21.0% during the forecast period 2023-2030.
-> North America and Europe are the two largest markets, each holding a share of about 32%.
-> The market is segmented into single-use bioreactors, disposable sterile bags, and disposable filtration systems. Disposable sterile bags hold the largest share at approximately 45%.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates